MELBOURNE, May 14, 2026, 05:01 AEST
CSL Limited shares steadied on Wednesday after a sharp selloff, but the market’s view of the Australian biotech has shifted hard after the company warned of about US$5 billion in fresh non-cash impairments and cut its fiscal 2026 outlook. The stock closed at A$98.79, up 0.24% on the day but down 58.8% over the past 12 months, market data showed.
The issue now is not just one bad trading update. CSL, once treated by many Australian investors as a defensive healthcare compounder, is trying to restore confidence while it has no permanent chief executive and while the 2022 Vifor deal continues to weigh on earnings, valuation and trust in management’s forecasts. Reuters reported the shares fell 16% on Monday to their lowest since January 2017 after the guidance cut.
CSL now expects FY26 revenue of about US$15.2 billion and NPATA of about US$3.1 billion on a constant-currency basis, which strips out exchange-rate swings. NPATA is net profit after tax before amortisation of acquired intellectual property and large one-off items such as restructuring and impairment costs.
Interim Chief Executive Gordon Naylor, who took the role in February, said in the company’s update that CSL’s “growth initiatives are working,” but the financial benefits would take longer than previously expected. “As a result, we have now revised down our 2026 financial year guidance,” he said.
The charge is an accounting writedown, not a cash outflow, but it still matters. CSL said the impairments would be booked across FY26 and FY27 and include CSL Vifor intangible assets, including product portfolio value, as well as under-used property, plant and equipment.
The pressure points are clear. CSL said U.S. immunoglobulin revenue would take an about US$300 million hit as channel inventory normalises; immunoglobulins are antibody-based plasma medicines used to treat immune disorders. It also flagged a roughly US$200 million revenue impact from lower albumin market value in China, plus about US$150 million from the Middle East conflict, slower Hemgenix growth and competition in iron treatments.
“Back-to-back downgrades do raise legitimate questions about the company’s visibility into its own business,” Mark Gardner, founder and CEO of Sydney-based MPC Markets, told Reuters. He said CSL was still in a “complex transformation” and was dealing with the fallout from an “overpriced acquisition.” Sahm
Morningstar analyst Shane Ponraj wrote on Wednesday that the market had been “blindsided” by guidance below FactSet consensus and that “there is much to do to turn CSL around.” He cut Morningstar’s fair value estimate for CSL by 21% to A$165, citing lower plasma profitability and fiercer competition. Morningstar
Competition is part of the reset. Morningstar said CSL remains one of three top-tier plasma therapy companies, but newer recombinant and gene-therapy products could eat into some plasma uses; it also pointed to Roche’s Hemlibra as pressure in haemophilia and said CSL is the second-largest influenza vaccine maker behind Sanofi.
CSL’s vaccine arm offered a more constructive update on Wednesday. CSL Seqirus said a JAMA Network Open study of about 430,000 U.S. adults aged 65 and older found no significant difference in effectiveness between adjuvanted and high-dose influenza vaccines; Chief Medical Officer Gregg Sylvester said the data added evidence of “comparable protection” in older adults. Global Newsroom | CSL
But the risk is that investors are not looking at the vaccine study first. If U.S. immunoglobulin inventory normalisation lasts longer than CSL expects, China albumin pricing stays weak, or generic competition in Vifor’s iron portfolio deepens, the August full-year results could bring more pressure rather than a clean break from the downgrade cycle. The company also said the impairments remain subject to further analysis, business developments, audit and board approval.
CSL said the global search for a permanent CEO was progressing, with Naylor expected to return to the board as a non-executive director after the handover. Chief Commercial Officer Andy Schmeltz will retire for personal reasons, and Diego Sacristan will take over commercial leadership for CSL Behring and CSL Vifor from July 1.
